+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metabolomics Services Market by Area of Application, Type of Metabolomics Service Offered, Type of Metabolome Profiling Technique Used, Type of End User and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • ID: 5578616
  • Report
  • April 2022
  • Region: Global
  • 245 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 1st BASE
  • Cedars-Sinai
  • Human Longevity
  • metaSysX
  • Philips
  • Thermo Fischer Scientific
Since the initiation of the Human Metabolome Project in 2005, the metabolomics technique has gathered significant attention from the industry stakeholders. It is worth mentioning that about 40,000 small molecules constitute the human metabolome. Further, 30% of the known genetic disorders are associated with small-molecule metabolism. Therefore, metabolome profiling can assist in obtaining a better understanding of the disease. The approach has also demonstrated to be capable of identifying new biomarkers (for diagnosis and prognosis) and novel drug targets. In fact, 50% of the total drug candidates are reported to emanate from pre-existing metabolites. Integration of metabolomics with development projects holds the potential to significantly improve the efficiency and success rate of drug discovery, owing to its ability to differentiate promising candidates in the early stages. As a result, metabolomics has become an indispensable part of modern drug discovery and development process and disease diagnosis. Further, with the growing prominence of personalized medicine, there is an increased demand for rapid, highly sensitive and accurate quantification methods, such as metabolomics, to analyze clinical specimens. It is worth highlighting that various types of metabolite detection techniques, including targeted metabolomics and untargeted metabolomics, are being employed for diagnosis, severity determination and therapy development efforts against COVID-19. Specifically, studies have reported the potential implications of the serum metabolome in understanding the pathophysiology of the aforementioned disease.

Given the growing pipeline of biomarkers and drug discovery projects, the current demand for metabolite profiling is high. In this context, more than 18,000 drug candidates are being evaluated across different development stages, at present. Although some pharmaceutical companies have established in-house metabolomics research capabilities, significant capital investments and specialized requirements render this approach prohibitive for most stakeholders. Moreover, the associated metabolomics technologies, including chromatography and spectrometry, are complicated by multi-step analytical protocols and technically demanding expertise, which eventually leads to contamination of samples and lack of reproducibility in test results. This has created a demand for service providers having the required expertise in the global metabolomics market. In fact, since 2000, more than 70 players offering metabolomics services have been established. Amidst growing competition in the metabolomics services market, the implementation of cutting-edge tools and technologies, such as artificial intelligence, big data analytics, deep learning, machine learning and quantum computing, serves to differentiate the offerings of stakeholders. Hence, several service providers engaged in this upcoming market have actively begun expanding their respective service portfolios, either through undertaking strategic acquisitions or forming alliances with other specialty companies. Considering the ongoing advancements and active research efforts, the metabolomics services market size is anticipated to be quadruple in the foreseen future.


Scope of the Report


The “Metabolomics Services Market by Area of Application (Biomarker Discovery, Personalized Medicine, Disease Diagnostics, Drug Discovery and Toxicological Testing), Type of Metabolomics Service(s) Offered (Targeted Metabolomics and Untargeted Metabolomics), Type of Metabolome Profiling Techniques Used (LC-MS, GC-MS and NMR), Type of End User (Research / Academic Institutes, Pharma / Biotech Firms and CROs) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the metabolomics services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing metabolomics services. 


Amongst other elements, the report features:

  • A detailed review of the overall landscape of companies offering metabolomics services to various organizations, including research / academic institutes, pharma / biotech firms and CROs, along with analysis based on various relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also provides details related to pre-profiling service(s) offered (experiment design and sample preparation), metabolomics service(s) offered (targeted metabolomics, untargeted metabolomics and unknown metabolite identification), additional services offered (lipidomics, metabolic flux analysis, proteomics, and xenobiotic metabolites analysis), type of metabolome profiling technique used (mass spectrometry, nuclear magnetic resonance, liquid chromatography, gas chromatography, inductively coupled plasma spectroscopy, capillary electrophoresis), type of approach used for data analysis (multivariate analysis, univariate analysis, preprocess and normalization, clustering analysis, enrichment analysis and classification and feature selection), type of biological sample analyzed (biological fluids, tissues, cells and stool), source of biological sample (animal, microbe, human and plant) and area of application (biomarker discovery, disease diagnostics, drug discovery, toxicological testing and personalized medicine). 
  • An in-depth analysis, highlighting the contemporary market trends, using eight schematic representations, including [A] waffle chart representations (based on regional distribution of various industry and non-industry players), [B] world map representations (based on the country-wise distribution of various industry and non-industry players), [C] a horizontally stacked bar chart representation (based on company / organization size and type of service provider), [D] a mekko chart representation (based on area of application and company / organization size), [E] a vertically stacked bar chart representation (based on type of metabolome profiling technique used and type of biological sample analyzed), [F] a tree map representation (based on type of metabolome profiling technique and area of application), [G] a 4D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, number of metabolomics services offered, company / organization size and region), [H] a grid representation (based on company / organization size, region, type of metabolomics services offered, type of metabolome profiling technique used and area of application).
  • An in-depth company competitiveness analysis of metabolomics service providers, segmented into four categories, namely large and very large (>500 employees), mid-sized (51-500 employees), small (11-50 employees) and very small companies (<10 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience) and portfolio strength (based on parameters, such as number of pre-profiling profiling services offered, number of additional services offered, type of metabolome profiling technique used, type of approach used for data analysis, type of biological sample analysed, source of biological sample analysed and area of application), as well as partnership activity (in terms of number of partnerships and type of agreement).
  • Elaborate profiles of various prominent players that are currently engaged in offering metabolomics services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked between several stakeholders engaged in providing metabolomic services, during the period 2014-2022, covering research agreements, R&D agreements, commercialization agreements, metabolomics data sharing agreements, acquisitions, service alliances, product development agreements and other agreements.
  • An insightful framework depicting the implementation of several advanced tools and technologies, such as artificial intelligence, big data analytics, block chain, cloud computing, deep learning, machine learning and quantum computing, at different stages of a metabolomics study, which can assist service providers in addressing existing unmet needs. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating above-mentioned technologies, based on the trends highlighted in published literature and patents.
  • One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for metabolomics services market in the next 13 years. Additionally, it features market size projections for the metabolomics services market, wherein both the current and upcoming opportunity is segmented across [A] area of application (biomarker discovery, personalized medicine, disease diagnostics, drug discovery and toxicological testing), [B] type of metabolomics service (targeted metabolomics and untargeted metabolomics), [C] type metabolome profiling technique (LC-MS, GC-MS and NMR), [D] type of end user (academic / research institutes, pharma / biotech firms, and CROs) and [E] key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.


The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Oliver Schimts (Head of Metabolome Data Science, BASF Metabolome Solutions)
  • Manoj Kumar (Indian Representative - Eroth Technologies, biocrates life sciences)
  • Bernhard Drotleff (Scientific Officer, European Molecular Biology Laboratory)
  • Morten Danielsen (Chief Executive Officer, MS-Omics)
  • Gilbert Skorski (Chairman and Chief Executive Officer, Phylogene)


Key Questions Answered

  • Who are the leading players engaged in providing metabolomics services?
  • Which metabolomics services are most commonly offered by service providers engaged in this market?
  • What is the relative competitiveness of metabolomics service providers?
  • What types of partnership models are commonly being adopted by stakeholders in this industry? 
  • What is the likely performance enhancement value upon integrating novel tools / technologies in metabolomics studies?
  • Which key market trends and driving factors are likely to impact the growth of the metabolomics services market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 1st BASE
  • Cedars-Sinai
  • Human Longevity
  • metaSysX
  • Philips
  • Thermo Fischer Scientific

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Metabolomics
3.3. Steps Involved in a Metabolomics Study
3.3.1. Experimental Design
3.3.2. Sample Preparation
3.3.3. Data Acquisition
3.3.4. Data Processing
3.3.5. Statistical Analysis
3.4. Approaches Used for Metabolomics Analysis
3.4.1. Targeted Metabolomics
3.4.2. Untargeted Metabolomics
3.4.3. Unknown Metabolite Identification
3.5. Applications of Metabolomics
3.6. Challenges Related to Metabolomics
3.7. Need for Outsourcing Metabolomics Operations
3.8. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Metabolomics Service Providers: Overall Market Landscape
4.3. Metabolomics Service Providers: Industry Players
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Type of Pre-Profiling Service(s) Offered
4.3.5. Analysis by Type of Metabolomic Service(s) Offered
4.3.6. Analysis by Type of Additional Service(s) Offered
4.3.7. Analysis by Type of Metabolome Profiling Technique Used
4.3.8. Analysis by Type of Approach Used for Data Analysis
4.3.9. Analysis by Type of Biological Sample Analyzed
4.3.10. Analysis by Source of Biological Sample
4.3.11. Analysis by Area of Application
4.4. Metabolomics Service Providers: Non-Industry Players
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Organization Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Type of Pre-Profiling Service(s) Offered
4.4.5. Analysis by Type of Metabolomic Service(s) Offered
4.4.6. Analysis by Type of Additional Service(s) Offered
4.4.7. Analysis by Type of Metabolome Profiling Technique Used
4.4.8. Analysis by Type of Approach Used for Data Analysis
4.4.9. Analysis by Type of Biological Sample Analyzed
4.4.10. Analysis by Source of Biological Sample
4.4.11. Analysis by Area of Application
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Location of Headquarters and Type of Service Provider (Waffle Chart and World Map Representation)
5.3. Analysis by Company / Organization Size and Type of Service Provider (Horizontally Stacked Bar Chart)
5.4. Analysis by Area of Application and Company / Organization Size (Mekko Chart)
5.5. Analysis by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed (Vertically Stacked Bar Chart)
5.6. Analysis by Type of Metabolome Profiling Technique Used and Area of Application (Treemap Representation)
5.7. Analysis by Year of Establishment, Company / Organization Size, Number of Metabolomics Service(s) Offered and Region (4D Bubble Chart)
5.8. Analysis by Company / Organization Size, Region, Type of Metabolomics Service(s) Offered, Type of Metabolome Profiling Technique Used and Area of Application (Grid Representation)
6. COMPANY COMPETITIVENESS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Very Small Companies
6.3.2. Company Competitiveness Analysis: Small Companies
6.3.3. Company Competitiveness Analysis: Mid-Sized Companies
6.3.4. Company Competitiveness Analysis: Large and Very Large Companies
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. biocrates life sciences
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. Creative Proteomics
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. DNA Xperts
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook
7.5. Eremid Research Services
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook
7.6. Human Metabolome Technologies (HMT)
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. Metabo Profile
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. Metabolon
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook
7.9. MS-Omics
7.9.1. Company Overview
7.9.2. Recent Developments and Future Outlook
7.10. Novelgene Technologies
7.10.1. Company Overview
7.10.2. Recent Developments and Future Outlook
7.11. Synbio Technologies
7.11.1. Company Overview
7.11.2. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Metabolomics Service Providers: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.2.1 Analysis by Year and Type of Partnership
8.3.2.2 Analysis by Type of Partnership and Company Size
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Type of Metabolomics Service(s) Offered
8.3.5. Analysis by Type of Metabolome Profiling Technique Used
8.3.6. Analysis by Area of Application
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.8.1 Local and International Deals
8.3.8.2 Intercontinental and Intracontinental Deals
8.3.8.3 Analysis by Location of Headquarters of Partner
8.3.8.4 Analysis by Type of Partnership and Location of Headquarters of Partner
9. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEED IN METABOLOMICS
9.1. Chapter Overview
9.2. Unmet Need in Metabolomics
9.3. Sensitivity and Selectivity: Key Tools and Technologies
9.3.1. Key Assumptions and Methodology
9.3.2. Dynamic Nuclear Polarization (DNP)
9.3.3. Technology B
9.3.4. Technology C
9.3.5 Results and Discussion
9.4. Data Processing: Key Tools and Technologies
9.4.1. Key Assumptions and Methodology
9.4.2. Artificial Intelligence
9.4.3. Technology E
9.4.4. Technology F
9.4.5. Technology I
9.4.6. Technology J
9.4.7. Technology K
9.4.8. Quantum Computing
9.4.9. Trends in Research Activity
9.4.10. Trends in Intellectual Capital
9.4.11. Results and Discussion
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Metabolomics Services Market, 2022-2035
10.4. Metabolomics Services Market: Analysis by Area of Application, 2022 and 2035
10.4.1. Metabolomics Services Market for Biomarker Discovery, 2022- 2035
10.4.2. Metabolomics Services Market for Personalized Medicine, 2022-2035
10.4.3. Metabolomics Services Market for Drug Discovery, 2022-2035
10.4.4. Metabolomics Services Market for Disease Diagnostics, 2022- 2035
10.4.5. Metabolomics Services Market for Toxicological Testing, 2022-2035
10.5. Metabolomics Services Market: Analysis by Type of Metabolomics Service Offered, 2022 and 2035
10.5.1. Metabolomics Services Market for Targeted Metabolomics, 2022-2035
10.5.2. Metabolomics Services Market for Untargeted Metabolomics, 2022-2035
10.6. Metabolomics Services Market: Analysis by Type of Metabolome Profiling Technique Used, 2022 and 2035
10.6.1. Metabolomics Services Market for LC-MS Technique, 2022-2035
10.6.2. Metabolomics Services Market for GC-MS Technique, 2022-2035
10.6.3. Metabolomics Services Market for NMR Technique, 2022-2035
10.7. Metabolomics Services Market: Analysis by Type of End User, 2022 and 2035
10.7.1. Metabolomics Services Market for Academic / Research Institutes, 2022-2035
10.7.2. Metabolomics Services Market for Pharma / Biotech Companies, 2022-2035
10.7.3. Metabolomics Services Market for Contract Research Organizations (CROs), 2022-2035
10.8. Metabolomics Services Market: Analysis by Key Geographical Regions, 2022 and 2035
10.8.1. Metabolomics Services Market in North America, 2022-2035
10.8.2. Metabolomics Services Market in Europe, 2022-2035
10.8.3. Metabolomics Services Market in Asia, 2022-2035
10.8.4. Metabolomics Services Market in Latin America, 2022-2035
10.8.5. Metabolomics Services Market in Middle East and North Africa (MENA), 2022-2035
10.8.6. Metabolomics Services Market in Rest of the World, 2022-2035
10.9. Concluding Remarks
11. CONCLUSION
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. BASF Metabolome Solutions
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Olivier Schmitz, Head of Metabolome Data Science
12.3. biocrates life sciences
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Manoj, Indian Partner (Eroth Technologies)
12.4 European Molecular Biology Laboratory (EMBL)
12.4.1. Company Snapshot
12.4.1. Interview Transcript: Bernhard Drotleff, Scientific Officer
12.5. MS-Omics
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Morten Danielsen, Chief Executive Officer
12.6. Phylogene
12.6.1. Company Snapshot
12.6.2. Interview Transcript: Gilbert Skorski, Chairman and Chief Executive Officer
13. APPENDIX I: TABULATED DATA14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Market Forecast
Figure 3.1 Steps Involved in a Metabolomics Study
Figure 3.2 Comparison between Mass Spectrometry and Nuclear Magnetic Resonance
Figure 3.3 Applications of Metabolomics
Figure 3.4 Challenges Related to Metabolomics
Figure 4.1 Metabolomics Service Providers: Distribution by Type of Service Provider
Figure 4.2 Metabolomics Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.3 Metabolomics Service Providers (Industry Players): Distribution by Company Size
Figure 4.4 Metabolomics Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 4.5 Metabolomics Service Providers (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 4.6 Metabolomics Service Providers (Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Figure 4.7 Metabolomics Service Providers (Industry Players): Distribution by Type of Metabolomics Service(s) Offered
Figure 4.8 Metabolomics Service Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.9 Metabolomics Service Providers (Industry Players): Distribution by Type Detection Technique Used
Figure 4.10 Metabolomics Service Providers (Industry Players): Distribution by Type of Separation Technique
Figure 4.11 Metabolomics Service Providers (Industry Players): Distribution by Type of Approach Used for Data Analysis
Figure 4.12 Metabolomics Service Providers (Industry Players): Distribution by Type of Biological Sample Analyzed
Figure 4.13 Metabolomics Service Providers (Industry Players): Distribution by Source of Biological Sample
Figure 4.14 Metabolomics Service Providers (Industry Players): Distribution by Area of Application
Figure 4.15 Metabolomics Service Providers (Non-Industry Players): Distribution by Year of Establishment
Figure 4.16 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size
Figure 4.17 Metabolomics Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Figure 4.18 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Figure 4.19 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Figure 4.20 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Metabolomics Service(s) Offered
Figure 4.21 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.22 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Figure 4.23 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Separation Technique Used
Figure 4.24 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Approach Used for Data Analysis
Figure 4.25 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Biological Sample Analyzed
Figure 4.26 Metabolomics Service Providers (Non-Industry Players): Distribution by Source of Biological Sample
Figure 4.27 Metabolomics Service Providers (Non-Industry Players): Distribution by Area of Application
Figure 5.1 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Figure 5.2 Key Insights: Distribution of Industry Players by Location of Headquarters (Country-wise)
Figure 5.3 Key Insights: Distribution of Non-Industry Players by Location of Headquarters (Country-wise)
Figure 5.4 Key Insights: Distribution by Company / Organization Size and Type of Service Provider
Figure 5.5 Key Insights: Distribution by Area of Application and Company / Organization Size
Figure 5.6 Key Insights: Distribution by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed
Figure 5.7 Key Insights: Distribution by Type of Metabolome Profiling Technique and Area of Application
Figure 5.8 Key Insights: Distribution by Year of Establishment, Company / Organization Size, Number of Metabolomics Service(s) Offered and Region
Figure 5.9 Key Insights: Distribution by Company / Organization Size, Region, Type of Metabolomic Service(s) Offered, Type of Metabolome Profiling Technique Used and Area of Application
Figure 6.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Figure 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.6 Company Competitiveness Analysis: Large and Very Large Companies
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Metabolomic Service(s) Offered
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Metabolome Profiling Technique Used
Figure 8.8 Partnerships and Collaborations: Distribution by Area of Application
Figure 8.9 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Figure 8.10 Partnerships and Collaborations: Distribution by Type of Metabolomics Service(s) Offered, Type of Metabolome Profiling Technique Used and Area of Application
Figure 8.11 Most Active Players: Distribution by Number of Partnerships
Figure 8.12 Partnerships and Collaborations: Local and International Agreements
Figure 8.13 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.14 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner (Country-wise)
Figure 8.15 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 9.1 Value Creation Framework: Likely Sensitivity Enhancement by Implementation of Key Tools and Technologies
Figure 9.2 Value Creation Framework: Comparison of Key Tools / Technologies
Figure 9.3 Value Creation Framework: Trends in Intellectual Property related to Integration of Key Tools and Technologies with Metabolomics
Figure 9.4 Value Creation Framework: Trends in Research Activity related to Integration of Key Tools and Technologies with Metabolomics
Figure 9.5 Value Creation Framework: Extent of Innovation versus Associated Risk Matrix
Figure 10.1 Global Metabolomics Services Market, 2022-2035 (USD Million)
Figure 10.2 Metabolomics Services Market: Distribution by Area of Application, 2022 and 2035
Figure 10.3 Metabolomics Services Market for Biomarker Discovery, 2022-2035 (USD Million)
Figure 10.4 Metabolomics Services Market for Personalized Medicine, 2022-2035 (USD Million)
Figure 10.5 Metabolomics Services Market for Disease Diagnostics, 2022-2035 (USD Million)
Figure 10.6 Metabolomics Services Market for Drug Discovery, 2022-2035 (USD Million)
Figure 10.7 Metabolomics Services Market for Toxicological Testing, 2022-2035 (USD Million)
Figure 10.8 Metabolomics Services Market: Distribution by Type of Metabolomics Service(s) Offered 2022 and 2035
Figure 10.9 Metabolomics Services Market for Targeted Metabolomics, 2022-2035 (USD Million)
Figure 10.10 Metabolomics Services Market for Untargeted Metabolomics, 2022-2035 (USD Million)
Figure 10.11 Metabolomics Services Market: Distribution by Type of Metabolome Profiling Technique Used, 2022 and 2035
Figure 10.12 Metabolomics Services Market for LC-MS Technique, 2022-2035 (USD Million)
Figure 10.13 Metabolomics Services Market for GC-MS Technique, 2022-2035 (USD Million)
Figure 10.14 Metabolomics Services Market for NMR Technique, 2022-2035 (USD Million)
Figure 10.15 Metabolomics Services Market: Distribution by Type of End User, 2022 and 2035
Figure 10.16 Metabolomics Services Market for Academic / Research Institutes, 2022-2035 (USD Million)
Figure 10.17 Metabolomics Services Market for Pharma / Biotech Companies, 2022-2035 (USD Million)
Figure 10.18 Metabolomics Services Market for Contract Research Organizations (CROs), 2022-2035 (USD Million)
Figure 10.19 Metabolomics Services Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Figure 10.20 Metabolomics Services Market in North America, 2022-2035 (USD Million)
Figure 10.21 Metabolomics Services Market in Europe, 2022-2035 (USD Million)
Figure 10.22 Metabolomics Services Market in Asia, 2022-2035 (USD Million)
Figure 10.23 Metabolomics Services Market in Latin America, 2022-2035 (USD Million)
Figure 10.24 Metabolomics Services Market in Middle East and North Africa (MENA), 2022-2035 (USD Million)
Figure 10.25 Metabolomics Services Market in Rest of the World, 2022-2035 (USD Million)
Figure 10.26 Metabolomics Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Million)
Figure 11.1 Concluding Remarks: Current Market Landscape
Figure 11.2 Concluding Remarks: Partnerships and Collaborations
Figure 11.3 Concluding Remarks: Value Creation Framework
Figure 11.4 Concluding Remarks: Market Forecast

List Of Tables
Table 4.1 Metabolomics Service Providers: List of Players
Table 4.2 Metabolomics Service Providers: List of Industry Players
Table 4.3 Metabolomics Service Providers (Industry Players): Information on Type of Pre-Profiling Service(s) Offered
Table 4.4 Metabolomics Service Providers (Industry Players): Information on Type of Metabolomic Service(s) Offered
Table 4.5 Metabolomics Service Providers (Industry Players): Information on Type of Additional Service(s) Offered
Table 4.6 Metabolomics Service Providers (Industry Players): Information on Type of Metabolome Profiling Technique Used
Table 4.7 Metabolomics Service Providers (Industry Players): Information on Type of Approach Used for Data Analysis
Table 4.8 Metabolomics Service Providers (Industry Players): Information on Type of Biological Sample Analyzed
Table 4.9 Metabolomics Service Providers (Industry Players): Information on Source of Biological Sample
Table 4.10 Metabolomics Service Providers (Industry Players): Information on Area of Application
Table 4.11 Metabolomics Service Providers: List of Non-Industry Players
Table 4.12 Metabolomics Service Providers (Non-Industry Players): Information on Type of Pre-Profiling Service(s) Offered
Table 4.13 Metabolomics Service Providers (Non-Industry Players): Information on Type of Metabolomic Service(s) Offered
Table 4.14 Metabolomics Service Providers (Non-Industry Players): Information on Type of Additional Service(s) Offered
Table 4.15 Metabolomics Service Providers (Non-Industry Players): Information on Type of Metabolome Profiling Technique Used
Table 4.16 Metabolomics Service Providers (Non-Industry Players): Information on Type of Approach Used for Data Analysis
Table 4.17 Metabolomics Service Providers (Non-Industry Players): Information on Type of Biological Sample Analyzed
Table 4.18 Metabolomics Service Providers (Non-Industry Players): Information on Source of Biological Sample
Table 4.19 Metabolomics Service Providers (Non-Industry Players): Information on Area of Application
Table 6.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Table 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 6.3 Company Competitiveness Analysis: List of Very Small Players
Table 6.4 Company Competitiveness Analysis: List of Small Players
Table 6.5 Company Competitiveness Analysis: List of Mid-sized Players
Table 6.6 Company Competitiveness Analysis: List of Large and Very Large Players
Table 7.1 Metabolomics Service Providers: List of Companies Profiled
Table 7.2 biocrates life sciences: Company Overview
Table 7.3 biocrates life sciences: Recent Developments and Future Outlook
Table 7.4 Creative Proteomics: Company Overview
Table 7.5 DNA Xperts: Company Overview
Table 7.6 Eremid Research Services: Company Overview
Table 7.7 Eremid Research Services: Recent Developments and Future Outlook
Table 7.8 Human Metabolome Technologies (HMT): Company Overview
Table 7.9 Human Metabolome Technologies (HMT): Recent Developments and Future Outlook
Table 7.10 Metabo Profile: Company Overview
Table 7.11 Metabo Profile: Recent Developments and Future Outlook
Table 7.12 Metabolon: Company Overview
Table 7.13 Metabolon: Recent Developments and Future Outlook
Table 7.14 MS-Omics: Company Overview
Table 7.15 MS-Omics: Recent Developments and Future Outlook
Table 7.16 Novelgene Technologies: Company Overview
Table 7.17 Synbio Technologies: Company Overview
Table 7.18 Synbio Technologies: Recent Developments and Future Outlook
Table 8.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership and Type of Partner, 2014-2022
Table 8.2 Partnerships and Collaborations: Information on Type of Agreement (Local / International and Intercontinental / Intracontinental), 2014-2022
Table 12.1 BASF Metabolome Solutions: Company Snapshot
Table 12.2 biocrates life sciences: Company Snapshot
Table 12.3 European Molecular Biology Laboratory (EMBL): Company Snapshot
Table 12.4 MS-Omics: Company Snapshot
Table 12.5 Phylogene: Company Snapshot
Table 13.1 Metabolomic Service Providers: Distribution by Type of Service Provider
Table 13.2 Metabolomics Service Providers (Industry Players): Distribution by Year of Establishment
Table 13.3 Metabolomics Service Providers (Industry Players): Distribution by Company Size
Table 13.4 Metabolomics Service Providers (Industry Players): Distribution by Location of Headquarters
Table 13.5 Metabolomics Service Providers (Industry Players): Distribution by Company Size and Location of Headquarters
Table 13.6 Metabolomics Service Providers (Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Table 13.7 Metabolomics Service Providers (Industry Players): Distribution by Type of Metabolomic Service(s) Offered
Table 13.8 Metabolomics Service Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Table 13.9 Metabolomics Service Providers (Industry Players): Distribution by Type Detection Technique Used
Table 13.10 Metabolomics Service Providers (Industry Players): Distribution by Type Separation Technique Used
Table 13.11 Metabolomics Service Providers (Industry Players): Distribution by Type of Approach used for Data Analysis
Table 13.12 Metabolomics Service Providers (Industry Players): Distribution by Type of Biological Sample Analyzed
Table 13.13 Metabolomics Service Providers (Industry Players): Distribution by Source of Biological Sample
Table 13.14 Metabolomics Service Providers (Industry Players): Distribution by Area of Application
Table 13.15 Metabolomics Service Providers (Non-Industry Players): Distribution by Year of Establishment
Table 13.16 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size
Table 13.17 Metabolomics Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Table 13.18 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Table 13.19 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Table 13.20 Metabolomics Service Providers (Non-Industry Players): Distribution by Metabolomics Service(s) Offered
Table 13.21 Metabolomics Service Providers (Non-Industry Players): Distribution by Additional Service(s) Offered
Table 13.22 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Table 13.23 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Table 13.24 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Approach used for Data Analysis
Table 13.25 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Biological Sample Analyzed
Table 13.26 Metabolomics Service Providers (Non-Industry Players): Distribution by Source of Biological Sample
Table 13.27 Metabolomics Service Providers (Non-Industry Players): Distribution by Area of Application
Table 13.28 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Table 13.29 Key Insights: Distribution of Industry Players by Location of Headquarters (Country-wise)
Table 13.30 Key Insights: Distribution of Non-Industry Players by Location of Headquarters (Country-wise)
Table 13.31 Key Insights: Distribution by Company / Organization Size and Type of Service Provider
Table 13.32 Key Insights: Distribution by Area of Application and Company / Organization Size
Table 13.33 Key Insights: Distribution by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed
Table 13.34 Key Insights: Distribution by Type of Metabolome Profiling Technique and Area of Application
Table 13.35 Company Competitiveness Analysis: Benchmarking of Services Strength
Table 13.36 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 13.37 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2022
Table 13.38 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.39 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.40 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 13.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.42 Partnerships and Collaborations: Distribution by Type of Metabolomics Service(s) Offered
Table 13.43 Partnerships and Collaborations: Distribution by Type of Metabolome Profiling Technique Used
Table 13.44 Partnerships and Collaborations: Distribution by Area of Application
Table 13.45 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Table 13.46 Most Active Players: Distribution by Number of Partnerships
Table 13.47 Partnerships and Collaborations: Local and International Agreements
Table 13.48 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 13.49 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner (Country-wise)
Table 13.50 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 13.51 Value Creation Framework: Distribution by Relative Sensitivity and Key Tools and Technologies
Table 13.52 Trends in Intellectual Property related to Integration of Key Tools and Technologies with Metabolomics
Table 13.53 Value Creation Framework: Extent of Innovation versus Associated Risk Analysis
Table 13.54 Value Creation Framework: Implementation of Key Tools / Technologies
Table 13.55 Metabolomics Services Market, 2022-2035 (USD Million)
Table 13.56 Metabolomics Services Market: Distribution by Area of Application, 2022 and 2035
Table 13.57 Metabolomics Services Market for Biomarker Discovery, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.58 Metabolomics Services Market for Personalized Medicine, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.59 Metabolomics Services Market for Disease Diagnostics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.60 Metabolomics Services Market for Drug Discovery, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.61 Metabolomics Services Market for Toxicological Testing, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.62 Metabolomics Services Market: Distribution by Type of Metabolomics Service(s) Offered, 2022 and 2035
Table 13.63 Metabolomics Services Market for Targeted Metabolomics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.64 Metabolomics Services Market for Untargeted Metabolomics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.65 Metabolomics Services Market: Distribution by Type of Metabolome Profiling Technique Used, 2022 and 2035
Table 13.66 Metabolomics Services Market for LC-MS Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.67 Metabolomics Services Market for GC-MS Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.68 Metabolomics Services Market for NMR Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.69 Metabolomics Services Market: Distribution by Type of End User, 2022 and 2035
Table 13.70 Metabolomics Services Market for Academic / Research Institutes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.71 Metabolomics Services Market for Pharma / Biotech Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.72 Metabolomics Services Market for Contract Research Organizations (CROs), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.73 Metabolomics Services Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Table 13.74 Metabolomics Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.75 Metabolomics Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.76 Metabolomics Services Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.77 Metabolomics Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.78 Metabolomics Services Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.79 Metabolomics Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.80 Metabolomics Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Million)
Note: Product cover images may vary from those shown
  • 1st BASE 
  • Abramson Cancer Center, Penn Medicine
  • Absorption Systems (acquired by Pharmaron)
  • Afekta Technologies
  • Agilent Technologies
  • Albert Einstein College of Medicine
  • Analytica Laboratories
  • AnGes
  • Anti-Doping Laboratory Qatar
  • ARC-BIO, Colorado State University
  • Arome Science
  • AstraZeneca
  • Augusta University
  • Australian Institute for Bioengineering and Nanotechnology (AIBN)
  • Axon Scientific
  • AXYS Analytical Services
  • AYOXXA
  • Barc Lab
  • BASF Metabolome Solutions
  • Bayer
  • Baylor College of Medicine
  • BERG
  • Beth Israel Deaconess Medical Center
  • Beth Israel Deaconess Medical Center (BIDMC)
  • BGI Genomics
  • biocrates life sciences
  • Biomedical Research Core Facilities, University of Michigan
  • Biosfer Teslab
  • Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles 
  • BioXenClue
  • BioZone 
  • Boehringer Ingelheim
  • Boston University
  • BPS Bioscience
  • Brigham and Women’s Hospital
  • Bristol Myers Squibb
  • CD BioSciences
  • CECAD, University of Cologne
  • Cedars-Sinai
  • Center for Iron and Hematology Disorders, University of Utah
  • Centre for Cellular and Molecular Platforms (C-CAMP)
  • Centre for Omic Sciences (COS)
  • Centre for Organismal Studies, Heidelberg University
  • Chalmers University of Technology
  • Champions Oncology
  • Chenomx
  • Children's Hospital of Philadelphia
  • CHUM Research Center
  • CIC bioGUNE Basque Research and Technology Alliance
  • Cincinnati Children's Hospital Medical Center
  • Clarus Analytical
  • Cleveland Clinic Lerner Research Institute
  • Cornell Institute of Biotechnology (CIB)
  • Creative Bioarray
  • Creative Biogene
  • Creative Proteomics 
  • Cytomics
  • Dana Faber Cancer Insitute
  • Department of Chemistry, University of Oxford
  • Diabetes Research Center, Washington University School of Medicine in St. Louis
  • DNA Genotek
  • DNA Xperts
  • Duke Center for Genomic and Computational Biology (GCB)
  • Duke-NUS Medical School
  • Eremid Research Services
  • European Molecular Biology Laboratory (EMBL)
  • Evotec
  • Faculty of Biology, Ludwig-Maximilians-Universität München
  • Firalis
  • Fraunhofer ITEM
  • Fred Hutchinson Cancer Research Center 
  • Frontage Laboratories
  • Functional Genomics Center Zurich (FGCZ)
  • Fundación MEDINA
  • Gemini Biosciences
  • General Metabolics
  • Georgetown Lombardi Comprehensive Cancer Center
  • Germans Trias i Pujol Research Institute (IGTP)
  • Gillings School of Global Public Health
  • Giotto Biotech
  • GlaxoSmithKline
  • Helmholtz Zentrum München
  • HRL Holdings
  • HTG Molecular Diagnostics
  • Human Longevity
  • Human Metabolome Technologies (HMT)
  • Humboldt Universität zu Berlin
  • Immuron 
  • Impulse Dynamics
  • Indiana Clinical and Translational Sciences Institute (CTSI)
  • Inivata
  • Institut Pasteur
  • Ion Source & Biotechnologies (ISB) 
  • IRBM
  • Irving Institute for Clinical and Translational Research
  • ITSI-BIOSCIENCES
  • James Hutton Institute
  •  John Innes Centre
  •  JUNO Metabolomics
  • J-VPD
  • Karolinska Institutet
  • Leiden University Medical Center
  • Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKUMed)
  • Lifeasible
  • Liquidia Corporation
  • M. J. Murdock Metabolomics Laboratory, Washington State University
  • Maastricht UMC+ 
  • MachPhy Solutions
  • Max Delbrück Center for Molecular Medicine
  • Max Planck Institute for Biology of Ageing
  • Max Planck Institute for Molecular Genetics (MPI-MG)
  • Max Planck Institute for Terrestrial Microbiology
  • Max Planck Institute of Immunobiology and Epigenetics
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medicilon
  • Merck
  • MetaboHUB
  • Metabolite Profiling Core Facility, Whitehead Institute
  • Metabolomics Core, North Carolina Diabetes Research Center
  • Metabolon
  • Metabolytica
  • Metabo-Profile 
  • Metanomics Health 
  • metaSysX 
  • Metdia Biotech
  • Monash University
  • Montreal Heart Institute
  • MRC Cancer Unit, University of Cambridge
  • MS-Omics
  • MtoZ Biolabs
  • MTT Lab
  • Muses Labs
  • MYOS Corporation
  • National Biomedical Resource Indigenisation Consortium (NBRIC)
  • National Insitute of Allergy and Infectious Diseases
  • National Institute on Aging
  • Nebraska Center for Biotechnology, University of Nebraska-Lincoln
  • Next Trillion Sciences
  • North Carolina Biotechnology Center (NCBiotech)
  • North Carolina Research Campus (NCRC)
  • North Carolina State University
  • Northwest Metabolomics Research Cente (NW-MRC)
  • North-West University (NWU)
  • Northwestern University
  • Novelgene Technologies
  • Novo Nordisk
  • numares
  • NuSirt Biopharma
  • NYU Langone Health
  • OmicsGen LifeSciences
  • Oncology Institute of Southern Catalonia
  • Osaka University
  • Ospedale San Raffaele
  • OWL 
  • Pacific Biosciences
  • Parker H
  • Perlman School of Medicine, University of Pennsylvania
  • Pharmacogenomics Laboratory, Université Laval
  • Pharmalegacy Laboratories
  • Pharmaron
  • PhenoSwitch Bioscience
  • Philippine Genome Center (PGC)
  • Philips
  • Phylogene 
  • PROMETHEUS METABOLOMICS 
  • ProSciento
  • Proteome Factory
  • Quintara Discovery (QDI)
  • Redox Biology Centre (RBC), University of Nebraska-Lincoln
  • Rosalind and Morris Goodman Cancer Institute, McGill University
  • Roy J
  • RTI International 
  • Rubio Laboratorios
  • Ruiyi Biotechnology
  • Rutgers Cancer Institute
  • Sagimet Biosciences
  • Sandor Speciality Diagnostics 
  • Sanyal Biotechnology
  • Sartorius 
  • SCIEX
  • Segal Cancer Proteomics Centre (SCPC) 
  • SGS 
  • Swedish Metabolomics Centre (SMC), SciLifeLab
  • Synbio Technologies
  • SYNLAB Group
  • System Biosciences (SBI)
  • Systems Biology Lab
  • Takeda
  • Technion-Israel Institute of Technology
  • Texas A&M University
  • TGA Sciences
  • The Arctic University of Norway (UiT)
  • The Australian Wine Research Institute (AWRI)
  • The Canadian Frailty Network
  • The Canadian Longitudinal Study of Aging
  • The Center for Innovative Technology (CIT), Vanderbilt University
  • The McMaster Institute for Research on Aging
  • The Metabolomics Innovation Centre (TMIC)
  • The Ohio State University
  • The University of Edinburgh
  • The University of Melbourne
  • The University of Tennessee Health Science Center
  • The University of Western Australia
  • The Wistar Institute
  • Thermo Fischer Scientific
  • Thomas Jefferson University
  • Turku Bioscience
  • U.S. Army Research Institute of Environmental Medicine
  • U.S. Department of Veterans Affairs
  • UCLA Metabolomics Centre
  • University of Alabama at Birmingham
  • University of Birmingham
  • University of California, Riverside
  • University of Cambridge
  • University of Colorado Anschutz Medical Campus
  • University of Copenhagen
  • University of Eastern Piedmont
  • University of Florida
  • University of Fribourg
  • University of Gothenburg
  • University of Helsinki
  • University of Lausanne
  • University of Louisville
  • University of Maryland School of Pharmacy
  • University of Minnesota
  • University of North Texas
  • University of Oklahoma
  • University of Oslo
  • University of Oxford
  • University of Texas at Dallas
  • University of Victoria (UVic)
  • University of Virginia
  • University of York
  • UT Southwestern Medical Center
  • UTMB Mass Spectrometry Facility (MSF) 
  • Utrecht University
  • Vanderbilt University
  • Verso Biosciences
  • Vienna BioCenter
  • W. M. Keck Metabolomics Research Laboratory, Iowa State University
  • Wake Forest School of Medicine
  • Washington University School of Medicine
  • Weill Cornell Medicine
  • Weizmann Institute of Science
  • West Coast Metabolomics Center
  • Xell (acquired by Sartorious)
  • X-omics
  • Yale University
  • Yenepoya Research Center (YRC)
  • Zhejiang Dian Diagnostics
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...